ProCE Banner Events

Share

Rapidly Evolving Treatment Landscape for R/R Myeloma: Integrating the Latest Data to Transform Care

Learn about and explore clinical pharmacist scenarios with use of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma in this interactive 1-hour webinar discussion with experts. Speakers will describe ways for pharmacists to prevent and manage toxicities, promote adherence, and contribute to a team-based environment to improve patient care.

This event has expired. No longer available for credits.

Credits Available

This activity is approved for 1.0 contact hours (0.1 CEUs) in states that recognize ACPE providers.

Who Should Attend

The target audience for this activity is pharmacists who care for patients with relapsed/refractory multiple myeloma as well as other stakeholders in hematology/oncology practice.

Time and location

Thursday, July 07, 2022

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

Agenda

Agenda is a conversation between the faculty about the topics below:

  • Current treatment pathways in relapsed/refractory multiple myeloma
  • Scenarios commonly observed at first relapse and refractory to multiple lines of treatment including counseling points, AE management, and adherence
  • Optimizing integration of newer agents into current algorithms
  • Emerging therapies

CME/CE Info

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-196-L01-P has been assigned to this live application-based activity (initial release date 7/7/2022). This activity is approved for 1.0 contact hours (0.1 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-196-L01-P has been assigned to this live application-based activity (initial release date 7/7/2022). This activity is approved for 1.0 contact hours (0.1 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Acknowledgement

This activity is supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC. and Karyopharm Therapeutics.

Additional Information

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.